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ABSTRACT 
SARAH R. UZENOFF: A Preliminary Trial of Adherence-Coping-Education (ACE) 
Therapy for First-Episode Schizophrenia 
(Under the direction of David Penn, PhD) 
 
A randomized controlled trial was conducted to examine the effectiveness of 
Adherence-Coping-Education (ACE) Therapy. Twenty-four individuals were randomized to 
receive 14 sessions of either ACE therapy in addition to treatment as usual (TAU), or 
Supportive Therapy (ST) in addition to TAU. Participants were assessed on measures of 
medication attitudes, insight, symptoms, and social functioning.  ACE therapy was well 
tolerated, with comparable attrition rates between the two interventions and high therapy 
attendance. ACE Therapy was associated with significant improvements in medication 
attitudes as well as psychotic symptoms, insight and functioning. A greater proportion of 
individuals in the ACE condition had clinically significant change on positive symptom 
scores than did those in the ST condition. These results lend initial support for the feasibility 
of ACE Therapy, and suggest that it may facilitate recovery from an initial psychotic episode. 
Findings are discussed within the context of the study’s limitations. 
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A PRELIMINARY TRIAL OF ADHERENCE-COPING-EDUCATION (ACE) 
THERAPY FOR FIRST-EPISODE SCHIZOPHRENIA 
A central challenge in the treatment of schizophrenia is to prevent relapses, which are 
both costly (Weiden & Olfson, 1995) and dangerous (Swartz et al., 1998). Relapse 
prevention is of paramount concern for individuals recovering from their first episode of 
schizophrenia, as relapse rates of up to 33% are reported within one year of initial 
hospitalization (Ucok, Polat, Cakir, & Genc, 2006) and to over 90% within 5 years of initial 
treatment response (Perkins, Gu, Boteva, & Lieberman, 2005).  Such relapses may 
themselves be neurotoxic, as repeated relapse and rehospitalization is associated with 
progressive loss of brain grey matter and ventricular enlargement, which may lead to long-
term functional decline (Perkins et al., 2004; Waddington, Scully, & O'Callaghan, 1997).   
Medication nonadherence is among the strongest factors associated with relapse in 
schizophrenia (Kane, 1999): it is estimated that the risk of relapse for nonadherent 
individuals is more than three times greater than that for adherent individuals (Fenton, Blyler, 
& Heinssen, 1997). Medication non-adherence is a particular problem for individuals with 
first episode psychosis, with rates of nonadherence estimated between 19-40% at one year 
and as high as 75% at 2 years (Kampman et al., 2002; Perkins, 1999; Robinson et al., 2002). 
This is significant in that poor medication adherence during the first 6 months after an 
individual’s initial presentation strongly predicts poor adherence throughout the first 2 years 
of treatment, and is associated with an episodic course of illness and involuntary readmission 
(Verdoux et al., 2000).  Additionally, research suggests that there is a ‘critical period’ (i.e. 
2within 2-3 years of initial treatment) when psychosocial influences (such as reducing 
treatment resistance and influencing how individuals conceptualize their illness) may be most 
effective (Birchwood, Todd, & Jackson, 1998). For these reasons, it is essential that 
individuals with schizophrenia remain adherent and engaged with their treatment early in the 
course of their illnesses.  
The importance of medication adherence in the successful treatment of psychotic 
disorders is typically addressed via psychoeducation. However, findings suggest that 
psychoeducation has little impact on medication adherence rates in randomized controlled 
trials (Gray, Wykes, & Gournay, 2002; Mueser et al., 2002; Zygmunt, Olfson, Boyer, & 
Mechanic, 2002). This may reflect the fact that nearly two-thirds of first-episode patients 
have significant impairments in insight (Keshavan, Rabinowitz, DeSmedt, Harvey, & 
Schooler, 2004). Additionally, a majority of individuals recovering from a first episode of 
psychosis will have no residual positive or negative symptoms after the first year of treatment 
(Robinson et al., 1999) and therefore underestimate or fail to understand their potential to 
relapse. The Health Belief Model (HBM) of treatment adherence in preventative healthcare 
suggests that in order to arrive at an adherence decision, one must first perceive their own 
vulnerability to relapse, and also believe that medications will be efficacious in preventing 
relapse (Becker & Maiman, 1975). An important premise of this approach is that an 
individual’s beliefs, attitudes and goals are important determinants of adherence decisions. 
Thus, a therapeutic intervention that addresses medication adherence must necessarily 
explore client beliefs and attitudes in a systematic way—an approach typically adopted by 
cognitive behavioral therapy (CBT). 
3CBT has consistently shown to be effective at reducing persistent positive and 
negative symptoms of schizophrenia (Dickerson, 2000; Rector & Beck, 2001; Tarrier, 2005; 
Zimmermann, Favrod, Trieu, & Pomini, 2005).  Additionally, recent trials of CBT for first-
episode psychosis have shown benefits in a number of outcome domains (Addington & 
Gleeson, 2005; Penn, Waldheter, Perkins, Mueser, & Lieberman, 2005), including recovery 
from acute symptoms (Lewis et al., 2002; Tarrier, Haddock, & Lewis, 2004), improving 
individuals’ adaptation to the illness, quality of life, and attitudes towards treatment (Jackson 
et al., 1998; Jackson et al., 2001), and reducing suicidal ideation (Power et al., 2003). Though 
less extensively examined, cognitive behavioral interventions have also shown promise in 
improving medication adherence, albeit in chronically ill samples (Boczkowski, Zeichner, & 
DeSanto, 1985; Hayward, Chan, Kemp, & Youle, 1995). In particular, Compliance Therapy 
(CT) (Kemp, David, & Hayward, 1996a) has been associated with significantly greater 
improvement in attitudes towards medication, insight, and compliance with treatment as 
compared to a control group (Kemp, Hayward, Applewhaite, Everitt, & David, 1996b). 
Furthermore, at 18-months, individuals who received CT also showed greater improvement 
in global social functioning, as well as longer survival in the community prior to 
rehospitalization (Kemp, Kirov, Everitt, Hayward, & David, 1998).  These outcomes are 
noteworthy in that they demonstrate the potential for cognitive behavioral therapies to impact 
both adherence behavior and community functioning, as well essential underlying attitudes 
surrounding medication adherence (see Byerly, Fisher, Carmody, & Rush, 2005; O'Donnell 
et al., 2003 for conflicting findings).  
Perkins, Penn and Lieberman (unpublished manual) adapted CT to a first-episode 
sample by considering specific issues associated with an initial psychotic break (International 
4Early Psychosis Association Writing Group, 2005; Tarrier, Khan, Cater, & Picken, 2006), 
such as managing the trauma following an initial hospital admission and dealing with the 
stigma of mental illness. In addition, this modified intervention increased the number of 
therapy sessions, since the brevity of CT (4-6 sessions) is likely inadequate for individuals 
with first-episode psychosis who typically undergo a long recovery process and for whom 
initial engagement may be difficult. Thus, Adherence-Coping-Education (ACE) Therapy was 
developed to enhance adherence to treatment, reduce the stigma associated with psychosis, 
and to improve functional outcomes among individuals with first-episode psychosis.  
The purpose of this study was to conduct a preliminary evaluation of the effectiveness 
of ACE Therapy compared to a control treatment (i.e. supportive therapy; ST). The primary 
hypotheses were that individuals receiving ACE would; 1) report greater medication 
adherence (i.e. less deviation from the medication regiment as prescribed), and 2) show a 
greater increase in positive attitudes toward their medication than individuals receiving 
Supportive Therapy (ST) at three months (mid-treatment) and six months (end of treatment). 
A secondary hypothesis was that individuals in the ACE group would show greater 
improvement in social functioning and insight, and a greater reduction in symptoms 
(psychotic and depressive) at mid-treatment and post-treatment than individuals in the ST 
group. 
Methods 
Research Design and Overview 
 We conducted a randomized, single blind, controlled clinical trial of ACE therapy. 
Participants were randomized to receive either ACE Therapy in addition to treatment as usual 
or ST in addition to treatment as usual. Both groups received their clinical treatment at the 
5same outpatient treatment clinic and all decisions about medications and other supportive 
therapies were made by their treating clinicians independent of study assignment.  Both 
therapy interventions consisted of a total of 14 therapy sessions over the course of 6 months: 
the first 6 sessions occurred on a weekly basis, followed by 8 biweekly sessions. 
Assessments were conducted at baseline, 3 months (mid-treatment), and 6 months (end of 
treatment) by interviewers blind to treatment condition.  
Participants 
 The sample comprised 24 participants recovering from a first psychotic episode. 
Participants were recruited from local inpatient and outpatient clinics, community mental 
health centers, and through media advertising and referrals from community clinicians. 
Brochures describing the study were mailed to area psychiatrists, psychologists, 
pediatricians, and social workers. Study inclusion and exclusion criteria were as follows: 16 
years of age or older; meets DSM-IV (APA, 2000) diagnostic criteria for schizophrenia, 
schizoaffective disorder, or schizophreniform disorder; has been in treatment for a first 
episode of psychosis for less than 12 months, and no known mental retardation.  
Measures 
 Screening. Eligibility for study participation was determined using the Structured 
Clinical Interview for DSM-IV Axis I Disorders (SCID-I)(First, 1996).  
Primary Outcomes. Medication adherence was assessed by patient report using the 
following prompts: “Over the past month/since your last visit, on how many days did you not
take/miss your medication?” (<7, 7-13, 14-20, >20); “Over the past 4 weeks/ since your last 
visit, how often did you take less than the prescribed dose?” (1=always, 2=usually, 
3=sometimes, 4=never, almost never); “In summary, over the past 4 weeks, how often did 
6you take your medication as prescribed?” (1=always, 2=usually, 3=sometimes, 4=never, 
almost never). 
The Rating of Medication Influences (ROMI) scale (Weiden et al., 1994) is a 
comprehensive measure of attitudes regarding adherence to antipsychotic medications. The 
measure is divided into two subscales, ‘Reasons for Adherence’ (9 items) and ‘Reasons for 
Nonadherence’ (10 items), each containing attitudinal and behavioral factors thought to 
influence adherence behavior. Items are rated on a 1 through 3 scale, where 1=no influence, 
2=mild influence, 3=strong influence, and 96=not applicable. Weiden et al. (1994) reported 
moderate internal consistency for both scales; in the current study, these subscales yielded 
Cronbach’s alphas of .53-.61. Higher scores on the ‘Reasons for Adherence’ subscale 
correspond to an endorsement of factors influencing the individual to take his/her 
medication, whereas higher scores on the ‘Reasons for Nonadherence’ subscale correspond 
to an endorsement of factors influencing the individual to stop taking his/her medication. 
In addition, health beliefs were evaluated using two scales developed to map onto the 
central constructs of the Health Belief Model; ‘Need for Treatment,’ and ‘Benefits of 
Medication’ (Perkins et al., 2006).  Each comprises selected items from the ROMI and the 
ITAQ (discussed below) and was found to have excellent internal reliability; in the current 
study, these subscales yielded Cronbach’s alphas of .81-.93. Perkins et al. (2006) found that 
both of these scales significantly predicted likelihood of medication nonadherence in a large 
sample of individuals recovering from a first psychotic episode. The Need for Treatment and 
Benefits of Medication scales are calculated as the average of the individual item scores and 
therefore had a range of 1-3 (ITAQ items were rescaled from 0-2 to 1-3). Higher scores 
indicate positive beliefs. 
7Secondary Outcomes. The Insight and Treatment Attitudes Questionnaire (ITAQ) 
(McEvoy et al., 1989) is designed to assess an individual’s recognition of illness and need for 
treatment. The ITAQ includes 11 questions. Reponses are rated as follows: 2=good insight, 
1=partial insight, and 0=no insight, which are summed to provide a total insight score; higher 
scores correspond to better insight. 
 The Positive and Negative Syndrome Scale (PANSS) is a structured clinical interview 
consisting of 30 items designed to assess positive, negative, mood, and behavioral symptoms 
over the last week (Kay, Fiszbein, & Opler, 1987). Items are scored from 1 (absent) to 7 
(severe) and yield three scaled scores: Positive Symptoms, Negative Symptoms, and General 
Psychopathology. Higher total scores correspond to greater severity of symptoms. The 
PANSS has demonstrated adequate internal reliability (* = .73-.83) and test-retest reliability 
(r = .77-.89).  Raters were trained to reliability (r > .80) by a gold-standard rater prior to the 
study.  
 Further information regarding participants’ symptom severity was collected using the 
Calgary Depression Rating Scale (CDRS) (Addington, Addington, & Maticka-Tyndale, 
1993), a 9-item structured interview scale developed specifically for assessing depression in 
individuals with schizophrenia. The CDRS has high internal consistency (* = .79) and 
assesses depression as separate from overlapping negative or extrapyramidal symptoms.
Higher scores correspond to greater depression. 
The Quality of Life Scale (QLS) (Heinrichs, Hanlon, & Carpenter, 1984) was used to 
assess social and vocational functioning.  This 21-item scale is based on a semi-structured 
interview providing information on symptoms and functioning during the preceding 4 weeks. 
Items are rated on a 7-point scale, with the high end of the scales (scores of 5 and 6) 
8reflecting normal or unimpaired functioning, and the low end of the scales (scores of 0 and 1) 
reflecting severe impairment of the function in question. Higher total scores indicate better 
social and vocational functioning. 
Interventions 
Both interventions (ACE and ST) were provided by clinicians with at least a Master’s 
degree and one year experience working with individuals with first-episode psychosis.  
Therapists were trained by one of the authors of the manual (DLP) via directed readings and 
role-plays. 
 ACE Therapy is a manual-based psychotherapy designed around the goals of; 1) 
enhancing insight into illness, 2) improving medication adherence, and 3) developing 
adaptive coping strategies.  ACE Therapy consists of 14 sessions that are delivered over a 6-
month period and are divided into 4 phases: (1) establishing therapeutic alliance; (2) 
promoting treatment adherence; (3) developing a plan for maintenance treatment; and (4) 
rehabilitation. In ACE Therapy, the therapist assumes an active role consistent with 
traditional cognitive-behavioral therapies, and the therapeutic stance emphasizes empathy for 
the patient’s point of view. Key therapeutic techniques utilized include: reflective listening, 
inductive questioning, evaluating the pros and cons (e.g., of medication use), summarizing, 
reframing, using normalizing rationales, selective validation of the patient’s beliefs and 
attitudes, and graded analysis of evidence to address beliefs about illness and treatment.  
Individuals randomized to ACE Therapy attended sessions held at weekly intervals for 
sessions 1 through 6, then every other week for sessions 7 through 14. Sessions lasted 
approximately 30-45 minutes.   
9Supportive Therapy (ST) was intended to control for the non-specific aspects of 
therapy, such as therapeutic relationship and regular contact with a therapist. The goals of ST 
are: 1) to provide an environment where the client can discuss her/his feelings and concerns; 
2) to validate the client’s feelings and concerns, and; 3) to provide support and guidance to 
the client so that she/he can make progress to solving problems or alleviating concerns and 
worries.  ST has two phases, which are; 1) establishing a therapeutic alliance, and 2) 
providing emotional support and discussing non-illness issues or topics. Therapists were 
instructed not to bring up or discuss issues related to medication or medication adherence.  If 
patients brought up these issues in ST, the therapist was to listen with an empathic 
therapeutic stance, and advise the patient to discuss these issues with his or her treating 
physician. Similar to subjects randomized to ACE Therapy, subjects randomized to ST 
received 14 sessions of therapy, each lasting approximately 30-45 minutes, delivered over a 
6-month period.  Sessions were held at weekly intervals for sessions 1 through 6, then every 
other week for sessions 7 through 14. 
Quality Assurance 
Each therapy session was audiotaped and reviewed by DLP for fidelity to the 
treatment and procedures. Performance was discussed in individual supervision with the 
therapist. An independent assessor blind to all patient data and to the audiotape selection 
procedure listened to a random sampling of 20 therapy tapes stratified according to therapy. 
The assessor assigned each tape to either the ACE or ST group. 
Procedure 
Eligibility for study participation was determined during a screening visit, at which 
time a diagnostic screen was conducted using the Structured Clinical Interview for DSM-IV 
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Axis I Disorders (SCID-I)(First, 1996) and informed consent was obtained.  Baseline 
assessments were conducted and participants were then randomized to treatment.  At mid-
treatment and post-treatment, the following variables were assessed: Medication adherence, 
attitudes towards medication, insight, symptom severity, and social and vocational outcomes. 
Data Analysis Overview 
 Two-tailed t-tests and T 2 analyses were used to compare the ACE and ST groups on 
demographic characteristics and outcome measures at baseline, as well as to compare 
dropouts with the participants who were included in final data analyses. Because this is a 
preliminary feasibility study of ACE, we primarily focused on within-group t-tests and effect 
sizes to evaluate changes on outcome measures at mid- and post-study. Specifically, the two 
interventions were compared on primary and secondary outcome measures first by 
examining within-group t-statistics for score changes from baseline to mid-study (i.e. 3 
months), as well as from baseline to post-study (i.e. 6 months). Additionally, within-group 
effect sizes were calculated for these same pre-post periods. Effect size calculations (i.e. 
Cohen’s d; Cohen, 1988) were evaluated based on accepted standards for ‘small to medium’ 
(0.2 U d <0.5), ‘medium to large’ (0.5Ud <0.8), and large (d - 0.8) effect sizes. In a secondary 
analysis of clinically significant change, we used Fisher’s exact tests to compare the 
proportion of participants assigned to each intervention who showed at least 25% or 50% 
reductions in PANSS positive subscale scores at mid-study and end-of-study assessments; 
these figures are recognized as more lenient or conservative (respectively) guidelines for 
meaningful psychotic symptom reductions in trials of psychotherapeutic interventions for 
schizophrenia (Durham et al., 2003; Tarrier et al., 1999).  Missing individual data points 
were replaced with group or scale means, as more sophisticated methods of imputation 
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require larger sample sizes. Individuals missing an entire scale at baseline (N=3) were 
excluded from all subsequent analyses on that particular variable. Data that were missing 
scale-wise at mid- and post-study assessments were replaced using a last observation carried 
forward (LOCF) technique for some analyses, as noted below.  
All outcome analyses were completed using a modified intent-to-treat sample 
consisting of individuals who completed both a baseline assessment and at least one follow-
up assessment (i.e. 3 months), and who had attended at least one session of their assigned 
intervention. Effect size analyses and significance tests were conducted with two different 
methods; 1) observed cases, and; 2) a last observation carried forward (LOCF) technique to 
estimate data at 6 months for participants in the modified intent to treat sample who did not 
complete an end-of-study assessment. The former technique examines what may be 
considered an “efficacy subset” (Lachin, 2000) of individuals who completed the study (i.e. 
attended a 6 month evaluation), whereas the LOCF technique is believed to yield a more 
conservative estimate of the treatment effect compared to that which would have been 
observed if the individual had remained in the study. 
Additionally, an exploratory analysis was conducted using observed data to examine 
treatment by time interactions on measures of medication attitudes, symptoms, insight, and 
functioning. Using the PROC MIXED command in SAS, linear mixed-effects regression 
models were computed using time and treatment group as fixed effects and random intercepts 
for each participant. The F tests for the mixed model were based on Kenward-Roger’s 
adjusted degrees of freedom solution, an approach specifically proposed for small sample 
settings. While we recognize that the small sample size in this study results in reduced 
12
power, we believe it is useful to explore this model to examine the kind of analysis 
appropriate for a study with a larger sample. 
Results 
Demographic and Outcome Variables at Baseline 
Twenty-nine individuals were referred to the study, met eligibility criteria and gave 
their consent to participate; of these, 24 were randomized. Figure 1 shows the participant 
flow throughout the study. Of the 24 participants randomized to receive treatment, a total of 
5 participants were excluded from outcome data analyses. One participant had missing data 
at baseline, and was therefore excluded from analyses. An additional 3 participants, 
representing 15.4% of participants assigned to ACE (N=2) and 9.1% of participants assigned 
to ST (N=1), did not attend any follow-up assessments (i.e. dropped out before mid-study). 
Finally, one participant in the ACE group was excluded as an age outlier (i.e. the individual’s 
age was more than three standard deviations above the randomized sample mean). Two 
participants dropped out before the end of the study; data at 6 months for these patients was 
estimated using a LOCF technique. There was no significant difference between total 
proportions of drop-outs in the two groups (Fisher’s Exact Test p=1.00, ns), and there were 
no significant differences in demographics or symptom measures between drop-outs and 
individuals included in the outcome analyses (all p-values >.05).  
Table 1 shows demographic data for the participants included in outcome analyses 
(N=19). Demographic data at baseline did not differ significantly for individuals randomized 
to receive ACE as compared to individuals randomized to receive ST, with the exception of 
participant age; participants in the ACE group were significantly older than those in the ST 
group (t(17)=2.43, p=.03). Thus, age was examined as a covariate in the exploratory mixed 
13
effects analysis. There were no significant differences between the two groups on outcome 
variables at baseline (all p-values >.05) including self-reported medication adherence.  
Quality Assurance 
The independent assessor correctly assigned 18 of 20 therapy tapes (90%) to the 
appropriate treatment group.  
Therapy Attendance 
In this study, a ‘minimum dose’ of therapy was considered to be 6 sessions, which for 
the ACE condition includes the first two phases of the therapy (i.e. “Establishing a 
Therapeutic Alliance” and “Promoting Treatment Adherence”). In the ST condition, this 
includes the first 2 sessions devoted establishing a therapeutic alliance and an additional 4 
sessions spent providing emotional support and discussing non-illness issues and topics.  
One hundred percent of participants (N=19) received a minimum dose of therapy. In 
both groups attendance was high. In the ACE group, 9 out of 10 participants (90%) attended 
14 sessions (range=12-14 sessions). In the ST group, 8 out of 9 participants (88.9%) attended 
14 sessions (range=9-14 sessions).  Between the ACE and ST conditions of the modified 
intent-to-treat sample, there was no significant difference in therapy session attendance 
(ACE: M=13.80, SD=0.63; ST: M=13.44, SD=1.67)  (t(17)=0.63, p=.54). The 2 participants 
included in the LOCF analysis, but not the observed cases analysis, both received a minimum 
dose of therapy.  
Primary Outcome Analyses 
At baseline, 100% of participants in both conditions indicated that they failed to take 
their medication fewer than 7 days of the previous month. One participant in the ACE 
condition reported ‘always’ taking less than the prescribed dose of medication, and ‘never’ 
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taking the medication as prescribed. However all other patients reported the highest level of 
adherence, and there were no significant differences between the groups. At mid-study, 
100% of participants in both conditions indicated that they failed to take their medication 
fewer than 7 days of the previous month, reported “never (or almost never)” taking less than 
the prescribed dose of medication, and, likewise, that they “always” took medication as 
prescribed. These results were replicated at 6 months, suggesting no difference between 
groups on self-reported adherence behaviors.  Therefore the remainder of the analyses will 
focus on medication attitudes as the primary outcome. 
Observed cases analysis. Means for all analyses are presented in Table 2. Participants 
in the ACE group showed stronger endorsements of reasons for adherence on the ROMI at 
both mid-study (i.e. 3 months) and post-test (i.e. 6 months) than at baseline. There were 
medium within-group effect sizes for the ACE group on the ROMI ‘Adherence’ subscale 
(see Table 2), although these changes were not statistically significant. Conversely, the ST 
group showed stronger endorsements for reasons for nonadherence at 3 and 6 months than at 
baseline on the ROMI ‘Nonadherence’ subscale. There was a large effect size on this 
measure at 3 months, and the increase in total ‘Reasons for Nonadherence’ for the ST group 
was statistically significant at 6 months (t(5)=-3.162, p<.05), representing a medium to large 
effect size. 
Participants in the ACE group showed improvement on the HBM scales at three and 
six months. There were significant within-group changes at 3 months for ACE participants 
on both the Need for Treatment scale (t(7)=-2.55, p<.05) and the Benefits of Medication 
scale (t(7)=-2.51, p<.05), with these changes corresponding to large and medium to large 
effect sizes, respectively. There was also a significant within-group change on the Benefits of 
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Medication scale for ACE participants at 6 months (t(7)=-2.55, p<.05) and medium to large 
effect sizes for both HBM measures at that time point.  There were no significant changes on 
these measures for the ST group, though there were small to medium and medium to large 
effect sizes for the score increases at six months.  
LOCF analysis. Using a last observation carried forward (LOCF) technique for 
primary outcome measures, results differed from those obtained using observed cases in the 
following ways: the post-test effect size for the ACE group’s ROMI Adherence scores falls 
into the small to medium range, as do the ST group’s Need for Treatment and Benefits of 
Medication effect sizes; and the increase in ROMI Nonadherence scores for the ST group at 
six months now approaches significance (t(7)=2.01, p=.09), though the effect size remains in 
the medium to large range. 
Secondary Outcome Analyses 
Observed cases. The ACE group showed significant reductions on the PANSS 
Positive and General symptom subscales at both three months (t(9)=4.06, p<.01; t(9)= 2.84,
p<.05) and six months  (t(8)=3.43, p<.01; t(8)=3.22, p<.05). These reductions correspond to 
large effect sizes. There was a medium effect size for the decrease in PANSS Negative scores 
in the ACE group at 6 months and a trend towards statistical significance (t(8)=2.21,
p=.058). The ACE group also improved significantly on the ITAQ, with a significant 
increase in insight scores at both three months (t(8)=-3.49, p<.01) and six months (t(7)=-
3.15, p<.05) and large effect sizes at both points. And finally, ACE participants showed a 
significant increase in QLS (quality of life) total scores from baseline to six months (t(8)=-
2.89, p<.05), which represents a medium effect size. There were no significant changes in 
CDRS (depression) scores for the ACE group. 
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For the ST group, there was a significant decrease in PANSS positive symptoms at 
three months (t(8)=3.10, p<.05), but not at six months. There were small to medium effect 
sizes at both time points. The ST group had no significant changes on the other PANSS 
subscale scores, or on the ITAQ or QLS. Finally, CDRS scores increased for the ST group, 
with a medium effect size at three months and a large effect size at six months. This change 
was in the direction of higher depression scores. 
LOCF analysis. Using a last observation carried forward (LOCF) technique for 
secondary outcome measures, results differed from those obtained using observed cases in 
that the increase in QLS total scores for the ACE group now approaches statistical 
significance (t(9)=-2.17, p=.058), though the effect size remains in the ‘medium’ range.   
Supplementary Analysis: Mixed Effects Model 
Mixed effects analyses were also conducted to evaluate differences between 
participants in the ACE and ST conditions over time. There was a significant time by 
treatment interaction for symptom reduction on PANSS positive subscale scores 
(F(2,31.9)=3.98, p<.05). Contrasts revealed significant between-group differences in change 
scores from baseline to 3 months (t(31.7)=2.26, p<.05) and from baseline to 6 months 
(t(32)=2.56, p<.05), with greater reductions in symptom scores for the ACE group than for 
the ST group. There was also a significant time by treatment interaction for symptom 
reduction on PANSS general subscale scores (F(2,31.8)=4.44, p<.05). Probing these 
interactions revealed significant between-group differences in change scores from baseline to 
3 months (t(31.3)=2.50, p<.05) and from baseline to 6 months (t(32)=2.63, p<.05), with 
greater reductions for the ACE group than for the ST group. However, the between-group 
difference in baseline scores for this variable was also significant, which likely accounts for 
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this significant interaction (MACE=34.00, MST=26.33) (t(38.7)=-2.33, p<.05)1. Results for 
PANSS positive and general scores remained statistically significant at the p<.05 level when 
age was included as a covariate at baseline. 
Time by treatment interactions approached statistical significance for insight (i.e., 
ITAQ scores) (F(2,30.7)=2.33, p=0.11) and Need for Treatment (F(2,28.5)=2.90, p=.07), 
each with significant between-group differences in change scores from baseline to 3 months 
[(t(28.3)=-2.23, p<.05) and (t(30.4)=-2.10, p<.05), respectively]; greater improvements in 
insight and treatment attitudes were observed in the ACE group than in the ST group.  These 
results generally paralleled the within group analyses.  
Clinically Significant Change 
As summarized in Table 3, a greater proportion of individuals demonstrated clinically 
significant change in PANSS positive scores (i.e. 25% or 50% reduction) in the ACE group 
than in the ST group, at both 3 months and 6 months. The difference in proportions 
approached significance for 25% reductions at 3 months (p=.07), as well as for 50% 
reductions at 6 months (p=.09). 
Discussion 
The purpose of this study was to conduct a preliminary evaluation of the effectiveness 
and feasibility of ACE Therapy in a single blind, randomized controlled trial. Participants 
were randomized to receive either ACE Therapy in addition to treatment as usual (TAU) or 
supportive therapy (ST) in addition to TAU. Both therapies were well-tolerated, with no 
significant difference in attrition rates between the two. Individuals receiving ACE therapy 
 
1 This is in contrast to the statistic obtained using an independent-samples t-test for baseline differences on 
PANSS general scores (t(17)=1.90, p=.075), reported earlier, and reflects greater degrees of freedom in the 
model. 
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showed significant improvements on attitudes towards medications and treatment, which is 
consistent with our hypotheses. Also consistent with our hypotheses, ACE participants 
showed a reduction in symptoms, and improvements in insight and social functioning at post-
treatment. There were no significant changes in depression in either treatment group.  And, 
with the exception of a decrease in positive symptoms at mid-study, there were no significant 
benefits of ST on any of the outcome measures. Analyses utilizing a LOCF technique to 
replace missing values at 6 months tended to result in reduced effects sizes, but rarely did the 
statistical significance of the findings change. And finally, there were no differences between 
groups on self-reported medication adherence behaviors. These findings are discussed in 
more detail below.  
The high rate of retention in ACE therapy (90%) supports the feasibility of this 
intervention with a first-episode population. This is especially important given that 
engagement is a significant challenge for this clinical population (Grazebrook et al., 2004). 
Interestingly, many of the changes on primary and secondary outcome measures for the ACE 
group were associated with medium to large effect sizes by three months, corresponding to 
approximately 9 sessions of therapy.  Given this finding, it may be that ACE therapy can be 
successfully implemented in a briefer protocol. This, in turn, may further strengthen therapy 
engagement if clients know that they need to commit to three, rather than six, months of 
treatment. 
ACE was associated with improvements in attitudes towards medications which were 
evident at mid-study and endured to post-treatment. These changes were fairly robust, as they 
were associated with medium to large effect sizes. Improved attitudes towards treatment are 
consistent with the goals of ACE therapy and are similar to findings from the initial trial of 
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Compliance Therapy (CT) (Kemp, Hayward, Applewhaite, Everitt, & David, 1996b; Kemp 
et al., 1998). Changes in treatment attitudes were considerably smaller in the ST group, as 
manifest in effect sizes.  Though these findings are very preliminary, the data suggest that 
ACE therapy may improve treatment attitudes in individuals recovering from an initial 
episode of psychosis. 
This study did not find any differences between interventions on self-reported 
medication adherence; there were ceiling effects wherein all patients fell into the highest 
category of adherence behavior. The rates of adherence reported here are extremely high as 
compared to the mean rates observed across adherence studies in the field, which have been 
reported at approximately 33% at baseline and 24% at follow-up (Dolder, Lacro, Leckband, 
& Jeste, 2003). Thus, it is likely that our measures were not sensitive enough to detect 
meaningful differences in adherence behaviors. Though common in antipsychotic adherence 
studies, self-report measures have the potential to exaggerate the degree of adherence 
(Velligan et al., 2006). Thus, we cannot draw conclusions about the impact of ACE on 
medication adherence at this time. 
Several of the largest effect sizes associated with ACE therapy were for symptom 
measures. Reduction in symptoms is widely reported in trials of cognitive-behavioral 
interventions for chronic or treatment-resistant schizophrenia (e.g. Durham et al., 2003; 
Gumley et al., 2003) as well as for first-episode psychosis (e.g. Tarrier et al., 2004). The 
large effect size for positive symptom reduction for the ACE group (ES=1.19) is similar to 
the mean within-group effect size for positive symptom reduction in a meta-analysis of 
studies of cognitive-behavioral interventions for schizophrenia (ES=1.31)(Rector & Beck, 
2001), though in general, patients in these studies had been ill longer. Additionally, 
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supplemental mixed effects analyses showed that ACE was associated with a greater 
decrease in symptoms at both three and six months as compared to ST. However, it is 
important to exercise caution in interpreting these data for two reasons.  First, psychotic 
symptom scores were higher (albeit non-significantly) for the ACE group at baseline than for 
the ST group; and second, this study was under-powered to adequately detect such 
differences between groups over time. Thus, these findings, while promising, clearly need to 
be replicated in a larger randomized controlled trial before confident conclusions can be 
drawn. 
Among our secondary outcomes, ACE therapy was also associated with significant 
increases in insight and functioning, which are outcome domains of particular importance in 
first-episode psychosis treatment. With regard to insight, the gains observed in this study 
may support the intervention’s broader aim of improving medication adherence as a means of 
relapse prevention. Individuals experiencing their first psychotic episode who show lower 
insight are at an increased risk of discontinuing their medications (McEvoy et al., 2006). 
Thus, given the association between insight and treatment adherence, the improvement in 
insight may have important clinical implications.  The findings also suggest that the benefits 
of cognitive-behavioral interventions for psychosis may extend to social functioning as well 
(at least as measured by the Quality of Life Scale). Given that individuals with first-episode 
psychosis who report poorer quality of life tend to be treatment nonadherent (Coldham, 
Addington, & Addington, 2002), interventions successful at engaging such individuals may 
impact not only functioning in social domains, but increase the likelihood of future adherence 
to treatment. 
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This study suffers from several limitations. First, the sample size was small, therefore 
resulting in findings that need replication with a larger sample.  Second, the ceiling effect on 
the medication adherence measure underscores the need to supplement client-reported 
adherence data with direct or objective measures such as pill count or electronic monitoring 
of pill caps.  Third, there was no follow-up data past the 6-month post-treatment assessment.  
Thus, evidence of the durability of ACE could not be examined.  
These limitations notwithstanding, the results of this study support the feasibility of 
ACE therapy and highlight several potential clinical benefits of the intervention. The current 
study is one of the first to examine the effectiveness of a CBT intervention for first-episode 
psychosis that is specifically tailored to addressing treatment adherence and attitudes. 
Findings suggest that cognitive-behavioral interventions may be effective in improving 
attitudes towards treatment as well as psychotic symptoms, insight and functioning for 
individuals recovering from an initial psychotic episode. 
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Table 1. Demographic Characteristics of Sample Included in Outcome Analyses 
 
Variable ACE ST Test statistic (df) p-value 
N=10 N=9  
Age (years), M (S.D.) 25.30 (5.95) 19.78 (3.53) t(17)= 2.43 .03* 
Gender, n (%)     
 Male 6 (60.0) 6 (66.6) T2(1) = .090 .76 
 Female 4 (40.0) 3 (33.3)   
Marital status, n (%)     
 Never married 8 (80.0) 7 (77.7) T2(3) = 4.03 .26 
 Married  2 (22.2)   
 Separated/divorced 2 (20.0)    
Ethnicity, n (%)     
 Caucasian 7 (70.0) 7 (77.7) T2(2) = 1.95 .38 
 African-American 3 (30.0) 1 (11.1)   
 Other  1 (11.1)   
Highest level of education, n (%) 
 Did not complete high school 
 High school/GED 
 Some college 
 College graduate/Technical degree 
 Advanced degree 
 
2 (20.0) 
2 (20.0) 
4 (40.0) 
1 (10.0) 
1 (10.0) 
 
3 (33.3) 
2 (22.2) 
1 (11.1) 
2 (22.2) 
 
T2(5) = 5.85 
 
.32 
Parent’s highest level of education, n (%) 
 Did not complete high school 
 High school/GED 
 Some college 
 College graduate/Technical degree 
 Advanced degree 
 
1 (10.0) 
 
2 (20.0) 
2 (20.0) 
4 (40.0) 
 
1 (11.1) 
 
1 (11.1) 
4 (44.4) 
2 (22.2) 
 
T2(5) = 3.75 
 
.59 
 
*p U .05 
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Table 2. Means, Within-group Effect Sizes, and Significance Tests for Primary and Secondary Outcome Measures
0 3 6 (Observed) 6 (LOCF) (0-3) (0-6) Observed (0-6) LOCF
M (SD) M (SD) M (SD) M (SD) ES p ES p ES P
ACE
Primary Outcomes
ROMI Adherence 15.11 (4.49) 16.89 (6.01) 17.38 (4.41) 16.33 (5.17) 0.40 .146 0.51+ .285 0.27 .329
ROMI Nonadherence 9.44 (4.90) 8.67 (3.04) 9.88 (4.12) 10.38 (2.77) -0.16 .713 0.09 .741 0.19 .689
Need for Treatment± 2.32 (0.41) 2.74 (0.35) 2.57 (0.48) 2.57 (0.48) 1.03++ .038* 0.60+ .065 .60+ .065
Benefits of Medication± 2.44 (0.38) 2.70 (0.27) 2.67 (0.33) 2.67 (0.33) 0.68+ .040* 0.59+ .038* .59+ .038*
Secondary Outcomes
PANSS Positive 15.60 (4.97) 9.80 (3.26) 9.67 (2.69) 9.40 (2.68) -1.17++ .003* -1.19++ .009* -1.25++ .004*
PANSS Negative 17.70 (7.06) 16.60 (7.47) 14.11 (5.18) 14.30 (4.92) -0.16 .426 -0.51+ .058 -0.48 .069
PANSS General 34.00 (9.26) 25.60 (4.27) 24.56 (3.91) 24.70 (3.71) -0.91++ .020* -1.02++ .012* -1.00++ .010*
CDRS 10.50 (3.38) 12.10 (2.81) 9.67 (0.87) 10.20 (1.87) 0.47 .153 -0.25 .512 -0.09 .823
ITAQ 14.33 (4.18) 19.33 (3.46) 17.88 (4.67) 18.33 (4.58) 1.20++ .008* 0.85++ .016* 0.96++ .009*
QLS Total# 62.90 (28.40) 67.11 (19.66) 76.78 (19.94) 75.70 (19.10) 0.15 .542 0.49 .020* 0.45 .058
ST
Primary Outcomes
ROMI Adherence 16.00 (4.06) 16.89 (2.52) 16.86 (4.22) 16.78 (3.73) 0.22 .647 0.21 .537 0.19 .729
ROMI Nonadherence 10.22 (2.73) 13.00 (3.78) 12.00 (2.76) 12.13 (2.48) 1.02++ .088 0.65+ .025* 0.70+ .085
Need for Treatment± 2.45 (0.45) 2.41 (0.55) 2.61 (0.45) 2.55 (0.45) -0.09 .827 0.36 .180 0.23 .518
Benefits of Medication± 2.38 (0.39) 2.45 (0.51) 2.60 (0.37) 2.48 (0.47) 0.18 .703 0.55+ .160 0.26 .673
Secondary Outcomes
PANSS Positive 13.78 (5.91) 11.78 (5.36) 11.25 (4.03) 12.11 (4.57) -0.34 .015* -0.43 .282 -0.28 .161
PANSS Negative 14.33 (5.29) 13.78 (5.54) 15.75 (7.85) 16.00 (7.38) -0.10 .805 0.27 .646 0.32 .562
PANSS General 26.33 (8.23) 27.22 (7.48) 26.13 (7.97) 27.56 (8.60) 0.11 .653 -0.02 .680 0.15 .646
CDRS 9.78 (0.97) 10.33 (2.40) 11.13 (3.83) 11.67 (3.94) 0.57+ .479 1.39++ .379 1.94++ .211
ITAQ 15.11 (4.86) 15.56 (5.81) 17.50 (4.75) 16.78 (4.94) 0.09 .829 0.49 .074 0.34 .287
QLS Totala 73.38 (33.89) 81.63 (24.25) 79.71 (25.91) 75.63 (26.63) 0.24 .245 0.19 .453 0.07 .721
±Health Belief Model constructs composed of select ROMI and ITAQ items. See Perkins et al. (2006) for variable construction.
+ 0.5UES<0.8, ++ ES ] 0.8, * p U .05
aThe mid-study scores in this table are observed—the QLS Total mean obtained at time 3 for the ACE condition using a LOCF technique is M=68.30 (18.92)
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Table 3. Clinically Significant Change on PANSS Positive Subscale Scores for ACE and ST 
 
Mid-study Post-test 
25% reductiona 50% reduction 25% reduction 50% reduction 
Count (%) Sig.b Count (%)   Sig. Count (%) Sig.  Count (%) Sig. 
ACE 8 (80%) p=.07 3 (30%)  p=.21 6 (60%) p=.37 4 (40%) p=.09 
ST 3 (33%)     0  3 (33%)    0 
 
a Participants who achieved a 50% reduction are included in both the 25% and 50% columns  
b Fisher’s Exact Test 
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Figure1. Study flow diagram 
aOne participant randomized to ST was missing all baseline data—all scores for this participant were excluded 
from analyses. Thus, data from 9 participants was available at 3 months, and from 8 participants at 6 months. 
 
b One participant assigned to the ACE group was excluded from outcome analyses as an age outlier. Thus, data 
was available from 10 participants at 3 months, and from 9 participants at 6 months. 
3 Month 
N=10a
3 Month 
N=11b
Dropout 
N=1 
Dropout 
N=2 
ACE Therapy 
Baseline N=13b
Supportive 
Therapy 
Baseline N=11a
Dropout 
N=1 
Dropout 
N=1 
Randomized 
N=24 
Recruited 
N=29 
Withdrawn Consent   
N=3 
Screen Fail N=2 
6 Month 
N=9a
6 Month 
N=10 b 
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